Ebola viral disease: What should be done to combat the epidemic in 2014?

Ebola virus disease (EVD) was defined first in 1976. Since then, more than 24 epidemics have been reported from Africa, predominantly with the Zaire species. On 21 March 2014, the current West Africa outbreak was reported by the World Health Organization, the largest one ever recorded. The Congo epidemic was reported in July 2014. It was considered that the two epidemics had unrelated origins with 96.8% identical genomic sequence of the virus. EVD outbreaks occurred in areas with limited resources but it has a potentially global effect due to the possibility of imported infection and the potential misuse of the virus as a bioweapon agent. Although EVD is a zoonotic disease with the reservoir of fruit bats, human-to-human transmission is essential in the spread of the infection. The case-fatality rate of EVD was reported as 70.8%. There is no approved prophylaxis, effective treatment, or licensed vaccine. Early diagnosis and isolation of the patients, contact tracing, appropriate use of personal protective equipment , and adherence to the guidance for safe funeral practices constitute the essential requirements to control the epidemics. This article provides a review of the literature regarding the characteristics and management of EVD outbreak.

Anahtar Kelimeler:

Viral disease, Ebola viral disease, outbreak, control of epidemic

Ebola viral disease: What should be done to combat the epidemic in 2014?

Keywords:

Viral disease, Ebola viral disease, outbreak, control of epidemic,

PDF

___

Polonsky JA, Wamala JF, de Clerck H, Van Herp M, Sprecher A, Porten K, Shoemaker T. Emerging filoviral disease in Uganda: proposed explanations and research directions. Am J Trop Med Hyg 2014; 90: 790–793.
World Health Organization. Ebola Hemorrhagic Fever. Geneva, Switzerland: WHO; 2010. Available at http://www. who.int/mediacentre/factsheets/fs103/en/. 3. MacNeil A, Rollin PE. Ebola and Marburg hemorrhagic fevers: neglected tropical diseases? PLoS Negl Trop Dis 2012; 6: e1546.
Bray M, Chertow DS. Epidemiology, pathogenesis, and clinical manifestations of Ebola and Marburg virus disease. UpToDate; 2014. Available at http://www.uptodate.com/contents/ epidemiology-and-pathogenesis-of-ebola-virus-disease. 5. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377: 849–862.
Bagcchi S. Ebola haemorrhagic fever in west Africa. Lancet Infect Dis 2014; 14: 375.
World Health Organization Ebola Response Team. Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections. N Engl J Med 2014; 371: 1481–1495.
Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis 2011; 204: 810–816.
Piot P, Bureau P, Breman G, Heymann D, Kintoki V, Masamba M, Mbuyi M, Miatudila M, Ruppol F, Nieuwenhove SV et al. Clinical aspects of Ebola virus infection in Yambuku area, Zaire, 1976. In: Pattyn S, editor. Ebola Virus Haemorrhagic Fever. Amsterdam, the Netherlands: Elsevier; 1978. pp. 17–21.
Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis 2007; 196: 364–371.
Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, Nichol ST, Ksiazek TG, Rollin PE. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 2007; 196: 142–147.
Kucharski AJ, Piot P. Containing Ebola virus infection in West Africa. Euro Surveill 2014; 19: 20899.
Gilsdorf A, Morgan D, Leitmeyer K. Guidance for contact tracing of cases of Lassa fever, Ebola or Marburg haemorrhagic fever on an airplane: results of a European expert consultation. BMC Public Health 2012; 12: 1014.
Fischer WA 2nd, Hynes NA, Perl TM. Protecting health care workers from Ebola: personal protective equipment is critical but is not enough. Ann Intern Med 2014; 161: 753–754.
World Health Organization. Interim Infection Prevention and Control Guidance for Care of Patients with Suspected or Confirmed Filovirus Haemorrhagic Fever in Health- Care Settings, with Focus on Ebola. Geneva, Switzerland: WHO; 2014. Available at http://apps.who.int/iris/ bitstream/10665/130596/1/WHO_HIS_SDS_2014.4_eng. pdf?ua=1&ua=1&ua=1.
Raabe VN, Borchert M. Infection control during filoviral hemorrhagic fever outbreaks. J Glob Infect Dis 2012; 4: 69–74.
World Health Organization. Case Definition Recommendations for Ebola or Marburg Virus Diseases. Geneva, Switzerland: WHO; 2014. Available at http://www.who.int/csr/resources/ publications/ebola/ebola-case-definition-contact-en. pdf?ua=1.
Centers for Disease Control and Prevention. Case Definition for Ebola Virus Disease (EVD). Atlanta, GA, USA: CDC; 2014. Available at http://www.cdc.gov/vhf/ebola/hcp/case- definition.html.
Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, editors. Fields Virology. 6th ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2006. pp. 1409–1448.
Rowe AK, Bertolli J, Khan AS, Mukunu R, Muyembe-Tamfum JJ, Bressler D, Williams AJ, Peters CJ, Rodriguez L, Feldmann H et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola haemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. J Infect Dis 1999; 179: 28–35.
Elliott LH, McCormick JB, Johnson KM. Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation. J Clin Microbiol 1982; 16: 704–708.
Towner JS, Sealy TK, Ksiazek TG, Nichol ST. High-throughput molecular detection of haemorrhagic fever virus threats with applications for outbreak settings. J Infect Dis 2007; 196: 205– 212.
World Health Organization. Consultation on Potential Ebola Therapies and Vaccines - Background Document for Participants. Geneva, Switzerland: WHO; 2014. Available at http://www.who.int/csr/disease/ebola/ebola-new- interventions-02-sep-2014.pdf?ua=1.